Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group. Swain SM, et al. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12. Lancet Oncol. 2020. PMID: 32171426 Clinical Trial.
HER2-targeted therapy has changed the natural history of HER2-positive metastatic breast cancer, with the dual blockade of pertuzumab and trastuzumab, with docetaxel, demonstrating an 8-year landmark overall survival rate of 37%. FUNDING: F Hoffmann-La Roche and Genentech. …
HER2-targeted therapy has changed the natural history of HER2-positive metastatic breast cancer, with the dual blockade of pertuzumab and tr …
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2023 May;13(2_suppl):568S-591S. doi: 10.1177/21925682231173597. Global Spine J. 2023. PMID: 37222100 Free PMC article. No abstract available.
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.
Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Cadiñanos Loidi J, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Escobar Salinas N, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Gomez Rosso R, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Martínez Robles E, Matteelli A, Mazza-Stalder J, Moschos C, Muñoz-Torrico M, Mustafa Hamdan H, Nakčerienė B, Nicod L, Nieto Marcos M, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB. Borisov S, et al. Eur Respir J. 2019 Dec 19;54(6):1901522. doi: 10.1183/13993003.01522-2019. Print 2019 Dec. Eur Respir J. 2019. PMID: 31601711 Free article.
Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu.
García MJ, Rivero M, Miranda-Bautista J, Bastón-Rey I, Mesonero F, Leo-Carnerero E, Casas-Deza D, Cagigas Fernández C, Martin-Cardona A, El Hajra I, Hernández-Aretxabaleta N, Pérez-Martínez I, Fuentes-Valenzuela E, Jiménez N, Rubín de Célix C, Gutiérrez A, Suárez Ferrer C, Huguet JM, Fernández-Clotet A, González-Vivó M, Del Val B, Castro-Poceiro J, Melcarne L, Dueñas C, Izquierdo M, Monfort D, Bouhmidi A, Ramírez De la Piscina P, Romero E, Molina G, Zorrilla J, Calvino-Suárez C, Sánchez E, Nuñez A, Sierra O, Castro B, Zabana Y, González-Partida I, De la Maza S, Castaño A, Nájera-Muñoz R, Sánchez-Guillén L, Riat Castro M, Rueda JL, Benítez JM, Delgado-Guillena P, Tardillo C, Peña E, Frago-Larramona S, Rodríguez-Grau MC, Plaza R, Pérez-Galindo P, Martínez-Cadilla J, Menchén L, Barreiro-De Acosta M, Sánchez-Aldehuelo R, De la Cruz MD, Lamuela LJ, Marín I, Nieto-García L, López-San Román A, Herrera JM, Chaparro M, Gisbert JP, On Behalf Of The Young Group Of Geteccu. García MJ, et al. J Clin Med. 2021 Sep 26;10(19):4402. doi: 10.3390/jcm10194402. J Clin Med. 2021. PMID: 34640421 Free PMC article.